clinical trial · NCT05884255
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Jiangsu HengRui Medicine Co., Ltd.·phase3·recruiting·n = 220
Advanced Gastroenteropancreatic Neuroendocrine TumorLutetium (177Lu) Oxodotreotide Injection；long-acting Octreotidelong-acting Octreotide
brief summary
The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.
started
Jul 6, 2023
primary completion
Dec 1, 2026
completion
Oct 1, 2030
last updated
May 19, 2026
official title
Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol